<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and risk factors for testicular cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and risk factors for testicular cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and risk factors for testicular cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Dror Michaelson, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aditya Bagrodia, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Begoña P Valderrama, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germ cell tumors (GCTs) account for 95 percent of testicular cancers and include both seminomas and nonseminomatous germ cell tumors (NSGCTs). Testicular sex cord-stromal tumors are the other predominant type of primary testicular malignancy  (
         <a class="graphic graphic_table graphicRef81626" href="/z/d/graphic/81626.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         .)
        </p>
        <p>
         The epidemiology and risk factors for the development of testicular germ cell tumors are discussed here. The clinical presentation and diagnosis of testicular germ cell tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">
          "Clinical features, diagnosis, and evaluation of gynecomastia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3065126450">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35. In the United States, approximately 9000 males are diagnosed with testicular cancer each year. Due to effective multimodality therapy, there are fewer than 500 deaths annually due to testicular cancer [
         <a href="#rid1">
          1
         </a>
         ]. Most patients with testicular cancer present with disease confined to the testicle (stage I disease) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">
          "Treatment of stage I seminoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2951.html" rel="external">
          "Management of stage I nonseminomatous germ cell tumors"
         </a>
         .)
        </p>
        <p>
         Worldwide, there are approximately 75,000 cases of testicular cancer and over 9000 deaths per year [
         <a href="#rid3">
          3
         </a>
         ].The worldwide incidence is lowest in Africa and Asia and highest in the Scandinavian countries, Germany, Switzerland, and New Zealand [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The incidence of testicular cancer has been increasing globally [
         <a href="#rid5">
          5-8
         </a>
         ], but the cause is unclear. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, the overall incidence of testicular germ cell tumors (GCTs) among males rose 44 percent (from 3.35 per 100,000 males in the period from 1973 to 1978 to 4.84 per 100,000 males in the period from 1994 to 1998) [
         <a href="#rid6">
          6
         </a>
         ]. The incidence of seminoma rose 62 percent, while the incidence of nonseminomatous germ cell tumors (NSGCTs) rose 24 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In observational data from 12 European countries, the incidence of GCTs increased by 1 to 6 percent per year [
         <a href="#rid5">
          5
         </a>
         ]. By contrast, mortality rates decreased or were stable in most regions, reflecting improvements in treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2019803472">
         <span class="h2">
          Ethnicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testicular cancer is less common among Black Americans, as the incidence in this population is estimated to be one-fourth that of White Americans [
         <a href="#rid9">
          9
         </a>
         ]. However, the incidence of testicular cancer in Black Americans may be increasing. In one observational study, the incidence of testicular cancer among Black Americans doubled between 1988 and 1992 and from 1998 to 2001 [
         <a href="#rid10">
          10
         </a>
         ]. In this population, the increase in incidence was higher for seminoma than for NSGCT (124 versus 64 percent).
        </p>
        <p>
         The incidence of testicular cancer is rising the fastest within the Hispanic American population [
         <a href="#rid11">
          11
         </a>
         ]. There also appears to be a higher risk of death among Black Americans, Native Americans, Filipinos, Hawaiians, and Hispanic Americans with testicular cancer [
         <a href="#rid12">
          12
         </a>
         ]. In an observational study of 16,086 cases of primary testicular cancer diagnosed during 1973 to 1999, these groups were initially diagnosed at more advanced disease stages. Even after adjustment for stage, histology, and period of diagnosis, the relative risk of dying from testicular cancer was higher for these groups when compared with non-Hispanic White Americans (1.4 to 3.6).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several risk factors are associated with the development of testicular cancer. Some risk factors predispose to the development of carcinoma in situ (CIS) and testicular germ cell tumors (GCTs), while others predispose to the development of other types of primary testicular malignancies (eg, certain genetic disorders are associated with increased incidence of sex cord stromal tumors).
        </p>
        <p class="headingAnchor" id="H1011335942">
         <span class="h2">
          Testicular and other genitourinary conditions
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Germ cell neoplasia in situ
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adults, both seminomas and nonseminomatous germ cell tumors (NSGCTs) are preceded by a premalignant condition called germ cell neoplasia in situ (GCNIS). GCNIS has been identified in 0.4 to 1.1 percent of males undergoing testicular biopsy because of infertility but appears to be less common in the general population. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ"
         </a>
         .)
        </p>
        <p>
         GCNIS is found in testicular tissue adjacent to GCTs (except spermatocytic seminoma) in approximately 90 percent of adult cases [
         <a href="#rid13">
          13
         </a>
         ]. It also is observed in all patient groups at risk for testicular cancer, including males with cryptorchid testicles (up to 5 percent) [
         <a href="#rid13">
          13-15
         </a>
         ], prior or contralateral testicular GCTs (5 percent) [
         <a href="#rid16">
          16-18
         </a>
         ], and androgen insensitivity [
         <a href="#rid13">
          13,19
         </a>
         ]. These observations suggest the possibility of a field defect, in which genetic or developmental events that produce gonadal dysfunction confer predisposition to malignancy over a wide area [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Contralateral testicular cancer'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">
          "Pathogenesis and clinical features of disorders of androgen action"
         </a>
         .)
        </p>
        <p>
         If GCNIS is left untreated, the risk of progression to invasive malignancy is approximately 50 percent in five years [
         <a href="#rid16">
          16
         </a>
         ]. Whether all cases of GCNIS eventually progress to invasive malignancy is unclear. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Cryptorchidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males with cryptorchidism (or testicular malposition) are at increased risk for testicular cancer. Approximately 10 percent of all testicular cancers occur in the setting of cryptorchidism. However, testicular malpositioning alone does not explain the increased risk of testicular cancer, as the normally descended testicle is involved in some patients with cryptorchidism and testicular cancer.
        </p>
        <p>
         Surgical repositioning of the testis (orchiopexy) may decrease the risk of testicular cancer. Further details on cryptorchidism and testicular cancer risk are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">
          "Undescended testes (cryptorchidism) in children: Management", section on 'Testicular cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Hypospadias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of testicular GCTs appears to be increased in males with a history of hypospadias, a congenital abnormality of the male urethra, foreskin, and penis that results in abnormal ventral placement of the urethral opening. In a health registry study from Denmark that included 5441 males with testicular GCTs, the incidence of cancer was significantly increased (relative risk 2.13, 95% CI 1.26-3.61) [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6583.html" rel="external">
          "Hypospadias: Pathogenesis, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Contralateral testicular cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small proportion (less than two percent) of males with testicular cancer will have a second (contralateral) testicular cancer, either at presentation or with a subsequent metachronous cancer [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         In one observational study, 29,515 cases of testicular cancer in males under the age of 55 were reported to the United States National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) program between 1973 and 2001 [
         <a href="#rid22">
          22
         </a>
         ]. In this study, approximately 175 males presented with a synchronous contralateral cancer (0.6 percent). The 15-year cumulative risk of a contralateral (metachronous) testicular cancer was 1.9 percent, which is similar to that reported in other studies with long-term follow-up [
         <a href="#rid24">
          24,25
         </a>
         ]. Observational data also suggest a decreased risk of metachronous contralateral testicular cancer among males whose primary testicular cancer was treated with platinum-based chemotherapy [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         The incidence of second cancers is similar to the incidence of GCNIS seen in patients with unilateral testicular cancer who undergo biopsy of the contralateral testicle at the time of orchiectomy. Males with contralateral GCNIS appear to be the group at primary risk for the development of contralateral testis cancer [
         <a href="#rid16">
          16,18
         </a>
         ]. This was illustrated in a series of 500 patients with testicular GCTs in whom the contralateral testicle was biopsied at the time of orchiectomy [
         <a href="#rid16">
          16
         </a>
         ]. Seven of 27 males with GCNIS developed later contralateral invasive cancer compared with none of the 473 without GCNIS. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3486191816">
         <span class="h3">
          Extragonadal germ cell tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males with extragonadal GCTs are at risk of developing both testicular GCNIS and invasive GCTs. The risk is most pronounced in those with retroperitoneal rather than mediastinal disease, and nonseminomatous histology. (See
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ", section on 'Extragonadal germ cell tumor'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3883962842">
         <span class="h2">
          Family history of testicular cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         A family history of testicular cancer is a potential risk factor for developing testicular cancer [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Among males with testicular GCT, approximately 1 to 3 percent have a family member with the disease, which suggests a potential hereditary predisposition [
         <a href="#rid29">
          29-31
         </a>
         ]. The relative risk of testis cancer is increased 6- to 10-fold in the brothers or sons of a patient with testicular cancer [
         <a href="#rid27">
          27,32-35
         </a>
         ]. Family and twin studies have suggested that the estimated heritability of testicular GCTs is as high as 49 percent [
         <a href="#rid36">
          36
         </a>
         ]. The clinical and pathologic manifestations of testicular GCTs in these families appear to be similar to those seen in nonfamilial cases [
         <a href="#rid37">
          37
         </a>
         ]. A few rare inherited disorders have been associated with an elevated risk of testicular cancer [
         <a href="#rid38">
          38
         </a>
         ]. An increased risk of testicular cancer has also been suggested with certain candidate chromosomal regions [
         <a href="#rid39">
          39-41
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among families with testicular GCTs compatible with X-linked inheritance, a locus has been suggested on chromosome Xq27. This locus may also predispose to undescended testes [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isochromosome 12p is present in most patients with testicular GCTs [
         <a href="#rid42">
          42,43
         </a>
         ]. In a series of 179 analyzed cases of testicular GCT, abnormal karyotypes were present in 101 (59 percent), and 79 of these had the isochromosome 12p abnormality [
         <a href="#rid43">
          43
         </a>
         ]. However, the role of this abnormality in familial GCTs is undefined. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors", section on 'Molecular markers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MicroRNA 371a-3p (miR-371a-3p) is a universal molecular hallmark of GCTs regardless of age, site of origin, or sex. The role of miR-371a-3p in GCT tumorigenesis is unknown [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Serum tumor markers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate-risk and low-risk single nucleotide polymorphisms, identified through genome-wide association studies, are thought to explain approximately one-third of father-to-son familial risk for testicular GCT [
         <a href="#rid36">
          36,45-47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DNA damage with deficient repair may be important in the development of testicular GCTs. Testicular GCTs are enriched for reciprocal loss of heterozygosity, a DNA double-strand break-enriched genomic signature. One observational study evaluated inherited DNA repair gene alterations in 205 unselected males with a testicular GCT. In this group, 20 males with 22 pathogenic germline DNA repair gene variants were identified, one-third of which were in the checkpoint kinase 2 (
         <em>
          CHEK2
         </em>
         )
         <em>
         </em>
         gene [
         <a href="#rid48">
          48,49
         </a>
         ]. Furthermore, those individuals with the loss-of-function
         <em>
          CHEK2
         </em>
         variants developed testicular GCT six years earlier than did those with
         <em>
          CHEK2
         </em>
         wild-type alleles.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3032371862">
         <span class="h2">
          Genetic disorders
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Klinefelter syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Klinefelter syndrome is associated with mediastinal extragonadal GCTs [
         <a href="#rid50">
          50-52
         </a>
         ] and Leydig cell tumors. (See
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males", section on 'Klinefelter syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">
          "Down syndrome: Clinical features and diagnosis", section on 'Urologic abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2887511329">
         <span class="h3">
          Down syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Down syndrome has been associated with testicular cancer [
         <a href="#rid52">
          52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males", section on 'Klinefelter syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">
          "Down syndrome: Clinical features and diagnosis", section on 'Urologic abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4191239503">
         <span class="h3">
          Peutz-Jeghers syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males with Peutz-Jeghers syndrome have an increased incidence of Sertoli cell testicular tumors. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2972.html" rel="external">
          "Testicular sex cord stromal tumors", section on 'Additional diagnostic evaluations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2139451820">
         <span class="h3">
          Carney complex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Carney complex are at increased risk for developing Sertoli cell tumors [
         <a href="#rid54">
          54
         </a>
         ]. Carney complex is an autosomal dominant disorder characterized by two major types of findings: pigmented lentigines and blue nevi on the face, neck, and trunk; and multiple tumors, both endocrine (testicular Sertoli cells and occasionally adrenal, pituitary, or thyroid) and nonendocrine (cutaneous, mammary, and atrial myxomas, and psammomatous melanotic schwannomas). (See
         <a class="medical medical_review" href="/z/d/html/100662.html" rel="external">
          "Carney complex"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2972.html" rel="external">
          "Testicular sex cord stromal tumors", section on 'Additional diagnostic evaluations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1831098513">
         <span class="h2">
          Hormonal factors
         </span>
        </p>
        <p class="headingAnchor" id="H3406858266">
         <span class="h3">
          Androgen insensitivity syndromes and mixed gonadal dysgenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intersex individuals with androgen insensitivity syndrome or mixed gonadal dysgenesis are at high risk of GCNIS, and germinal and nongerminal neoplasms in cryptorchid gonads [
         <a href="#rid55">
          55-57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">
          "Pathogenesis and clinical features of disorders of androgen action"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7471.html" rel="external">
          "Diagnosis and treatment of disorders of the androgen receptor"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3003.html" rel="external">
          "Testicular germ cell neoplasia in situ"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          In utero estrogenic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies suggest that higher exposure to estrogenic compounds in utero increases the risk of testicular GCT. In one case-control study, exposure to exogenous estrogens in utero was associated with a 4.9-fold increase in the risk of testicular GCT [
         <a href="#rid58">
          58
         </a>
         ]. However, a similar association was not observed for malignant GCTs arising in children younger than 15 years [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Additional, indirect evidence supporting a role for hormonal influences comes from a case-control study that found increased blood levels of organochlorine pesticides in males with testicular GCTs compared with matched controls [
         <a href="#rid60">
          60
         </a>
         ]. These persistent pesticides are known to bind to estrogen receptors, and exposure in utero or early in life may contribute to the risk of testicular GCTs.
        </p>
        <p>
         The role of diethylstilbestrol in the development of testicular cancer is controversial. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5427.html" rel="external">
          "Outcome and follow-up of diethylstilbestrol (DES) exposed individuals", section on 'Testicular and prostate cancers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2983950342">
         <span class="h2">
          Lifestyle factors
         </span>
        </p>
        <p class="headingAnchor" id="H1248379306">
         <span class="h3">
          Marijuana (cannabis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies suggest an association between marijuana (cannabis) and the risk of testicular GCTs. In several meta-analyses, the risk of testicular GCT was twice as high among those using marijuana on a regular basis (either frequently [ie, at least weekly] or chronically [ie, for more than 10 years]) versus those who never used marijuana [
         <a href="#rid61">
          61,62
         </a>
         ]. Another study in Swedish military conscription recruits found a similar increase among those with heavy marijuana use [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2395535446">
         <span class="h2">
          Other factors
         </span>
        </p>
        <p class="headingAnchor" id="H1542945193">
         <span class="h3">
          Testicular microlithiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The relationship between testicular microlithiasis (microcalcifications) and testicular malignancy is controversial, in part because microlithiasis is most frequently identified in males who are being assessed because of testicular symptoms. Microlithiasis is usually found by scrotal ultrasonography, as diffuse echogenic foci within the seminiferous tubules [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16286.html" rel="external">
          "Screening for testicular cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16286.html" rel="external">
          "Screening for testicular cancer", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
         The relationship between testicular microlithiasis and testicular malignancy was evaluated in a systematic review and meta-analysis of 33 reports in which males had been referred for testicular ultrasound [
         <a href="#rid65">
          65
         </a>
         ]. Among the 1347 males with testicular microlithiasis, the incidence of testicular GCTs or GCNIS was higher than those without testicular microlithiasis (risk ratio 8.5, 95% CI 4.5-16.1).
        </p>
        <p>
         Other data suggest that patients with testicular microlithiasis as well as features of testicular dysgenesis syndrome (cryptorchidism, infertility, contralateral GCT, disorder of sex development) are at the highest risk of developing testicular cancer [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
         However, the utility of this observation is limited, since the relatively high frequency of microlithiasis in healthy young males precludes using this finding as a screening tool for testicular cancer. In population-based screening studies, the incidence of microlithiasis ranges between 2.4 and 5.6 percent, which exceeds the incidence of testicular cancer in healthy young males by approximately 1000-fold [
         <a href="#rid68">
          68,69
         </a>
         ]. Furthermore, the incidence of microlithiasis appears to be higher when more sensitive equipment is used to perform the examinations [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3031831447">
         <span class="h3">
          HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased incidence of testicular GCTs, particularly seminomas, has been described in males living with human immunodeficiency virus (HIV) compared with males living without HIV infection. In a meta-analysis of seven studies with over 440,000 males with acquired immunodeficiency syndrome (AIDS) or HIV infection, there was a modest increase in the incidence of testicular cancer compared with the general population (standardized incidence ratio of 0.7 to 1.8) [
         <a href="#rid71">
          71
         </a>
         ]. The increase was limited to seminomas and does not impact the incidence of nonseminomatous GCTs [
         <a href="#rid72">
          72-74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">
          "HIV infection and malignancy: Management considerations", section on 'Testicular neoplasms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H132842207">
         <span class="h3">
          Infertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data suggest that male infertility is a potential risk factor for the development of testicular cancer, even in the absence of conditions such as cryptorchidism that are associated with both infertility and testicular cancer. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">
          "Causes of male infertility", section on 'Association with testicular cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1827388862">
         <span class="h3">
          Lack of risk with vasectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasectomy is
         <strong>
          not
         </strong>
         a risk factor for testicular cancer. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8094.html" rel="external">
          "Vasectomy", section on 'Testicular cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35. The incidence of testicular cancer has been increasing globally, but the cause is unclear. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Risk factors that are associated with the development of testicular cancer include (see
         <a class="local">
          'Risk factors'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Germ cell neoplasia in situ
         </strong>
         – In adults, both seminomas and nonseminomatous germ cell tumors (GCTs) are preceded by a premalignant condition called germ cell neoplasia in situ (GCNIS). If GCNIS is left untreated, the risk of progression to invasive malignancy is approximately 50 percent in five years. Whether all cases of GCNIS eventually progress to invasive malignancy is unclear. (See
         <a class="local">
          'Germ cell neoplasia in situ'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cryptorchidism
         </strong>
         – Males with cryptorchidism are at increased risk for testicular cancer. Surgical repositioning of the testis (orchiopexy) may decrease the risk of testicular cancer. (See
         <a class="local">
          'Cryptorchidism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">
          "Undescended testes (cryptorchidism) in children: Management", section on 'Testicular cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contralateral testicular cancer
         </strong>
         – Less than two percent of males with testicular cancer will have a second (contralateral) testicular cancer, either at presentation or with a subsequent metachronous cancer. (See
         <a class="local">
          'Contralateral testicular cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Family history of testicular cancer
         </strong>
         – A family history of testicular cancer is a potential risk factor for developing testicular cancer. (See
         <a class="local">
          'Family history of testicular cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genetic disorders
         </strong>
         – Klinefelter syndrome is associated with the development of testicular GCTs and Leydig cell tumors (a testicular sex cord stromal tumor). Down syndrome is associated with increased risk of testicular tumors. Peutz-Jeghers syndrome and Carney complex are associated with the development of Leydig cell tumors. (See
         <a class="local">
          'Genetic disorders'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2972.html" rel="external">
          "Testicular sex cord stromal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other factors
         </strong>
         – Other conditions potentially associated with an increased risk of testicular cancer include testicular microlithiasis, HIV infection, infertility, hormonal, and lifestyle factors, among others. However, these factors generally have a limited impact on the total incidence of testicular cancer. (See
         <a class="local">
          'HIV infection'
         </a>
         above and
         <a class="local">
          'Hormonal factors'
         </a>
         above and
         <a class="local">
          'Genetic disorders'
         </a>
         above and
         <a class="local">
          'Lifestyle factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1254012767">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William K Oh, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol 2019; 202:272.
          </a>
         </li>
         <li class="breakAll">
          Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols CR. Testicular cancer. Curr Probl Cancer 1998; 22:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bray F, Richiardi L, Ekbom A, et al. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006; 118:3099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015; 33:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology 2015; 3:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajendran VK, Nguyen M, Ellison LM. Testicular cancer patterns in African-American men. Urology 2005; 66:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 2005; 23:5757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woldu SL, Aydin AM, Rao AV, et al. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology 2018; 112:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggs ML, Schwartz SM. Differences in testis cancer survival by race and ethnicity: a population-based study, 1973-1999 (United States). Cancer Causes Control 2004; 15:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999; 83:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skakkebaek NE, Berthelsen JG, Müller J. Carcinoma-in-situ of the undescended testis. Urol Clin North Am 1982; 9:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batata MA, Chu FC, Hilaris BS, et al. Testicular cancer in cryptorchids. Cancer 1982; 49:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von der Maase H, Rørth M, Walbom-Jørgensen S, et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 1986; 293:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996; 14:3126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieckmann KP, Loy V, Büttner P. Prevalence of bilateral testicular germ cell tumours and early detection based on contralateral testicular intra-epithelial neoplasia. Br J Urol 1993; 71:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassio A, Cacciari E, D'Errico A, et al. Incidence of intratubular germ cell neoplasia in androgen insensitivity syndrome. Acta Endocrinol (Copenh) 1990; 123:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen PM, Giwercman A, Skakkebaek NE, Rørth M. Gonadal function in men with testicular cancer. Semin Oncol 1998; 25:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnack TH, Poulsen G, Myrup C, et al. Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study. J Natl Cancer Inst 2010; 102:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005; 97:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zequi Sde C, da Costa WH, Santana TB, et al. Bilateral testicular germ cell tumours: a systematic review. BJU Int 2012; 110:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kier MG, Lauritsen J, Almstrup K, et al. Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study. Ann Oncol 2015; 26:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blok JM, Groot HJ, Huele EH, et al. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. J Clin Oncol 2021; 39:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellesnes R, Myklebust TÅ, Bremnes RM, et al. Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. J Clin Oncol 2021; 39:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forman D, Oliver RT, Brett AR, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 1992; 65:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harland SJ. Conundrum of the hereditary component of testicular cancer. Lancet 2000; 356:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer 1997; 80:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong C, Lönnstedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001; 37:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutke Holzik MF, Rapley EA, Hoekstra HJ, et al. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 2004; 5:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han S, Peschel RE. Father-son testicular tumors: evidence for genetic anticipation? A case report and review of the literature. Cancer 2000; 88:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimdal K, Olsson H, Tretli S, et al. Familial testicular cancer in Norway and southern Sweden. Br J Cancer 1996; 73:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl 2006; 29:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Risco Kollerud R, Ruud E, Haugnes HS, et al. Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study. Br J Cancer 2019; 120:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litchfield K, Thomsen H, Mitchell JS, et al. Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches. Sci Rep 2015; 5:13889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mai PL, Friedlander M, Tucker K, et al. The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol 2010; 28:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutke Holzik MF, Sijmons RH, Sleijfer DT, et al. Syndromic aspects of testicular carcinoma. Cancer 2003; 97:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000; 60:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapley EA, Crockford GP, Teare D, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000; 24:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ono Y, Rajpert De-Meyts E, Guellaën G, Bulle F. Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis. Oncogene 2001; 20:5548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Echten J, Oosterhuis JW, Looijenga LH, et al. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromosomes Cancer 1995; 14:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fankhauser CD, Nuño MM, Murray MJ, et al. Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review. Eur Urol Focus 2022; 8:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litchfield K, Levy M, Huddart RA, et al. The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nat Rev Urol 2016; 13:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litchfield K, Holroyd A, Lloyd A, et al. Identification of four new susceptibility loci for testicular germ cell tumour. Nat Commun 2015; 6:8690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litchfield K, Levy M, Orlando G, et al. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat Genet 2017; 49:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor-Weiner A, Zack T, O'Donnell E, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature 2016; 540:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AlDubayan SH, Pyle LC, Gamulin M, et al. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol 2019; 5:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer 1995; 71:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasle H, Jacobsen BB, Asschenfeldt P, Andersen K. Mediastinal germ cell tumour associated with Klinefelter syndrome. A report of case and review of the literature. Eur J Pediatr 1992; 151:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dexeus FH, Logothetis CJ, Chong C, et al. Genetic abnormalities in men with germ cell tumors. J Urol 1988; 140:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieckmann KP, Rübe C, Henke RP. Association of Down's syndrome and testicular cancer. J Urol 1997; 157:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney JA. Carney complex: the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Semin Dermatol 1995; 14:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin HS. Tumors of the testis in intersex syndromes. Urol Clin North Am 2000; 27:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller J, Ritzén EM, Ivarsson SA, et al. Management of males with 45,X/46,XY gonadal dysgenesis. Horm Res 1999; 52:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weir HK, Marrett LD, Kreiger N, et al. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. Int J Cancer 2000; 87:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shankar S, Davies S, Giller R, et al. In utero exposure to female hormones and germ cell tumors in children. Cancer 2006; 106:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGlynn KA, Quraishi SM, Graubard BI, et al. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J Natl Cancer Inst 2008; 100:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney J, Shaw C, Stanley J, et al. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 2015; 15:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghasemiesfe M, Barrow B, Leonard S, et al. Association Between Marijuana Use and Risk of Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2:e1916318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callaghan RC, Allebeck P, Akre O, et al. Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011. Cancer Epidemiol Biomarkers Prev 2017; 26:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holm M, Hoei-Hansen CE, Rajpert-De Meyts E, Skakkebaek NE. Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle. J Urol 2003; 170:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan IB, Ang KK, Ching BC, et al. Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review. Cancer 2010; 116:4520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinkelman-Smit M. Management of Testicular Microlithiasis. Eur Urol Focus 2021; 7:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           't Hoen LA, Bhatt NR, Radmayr C, et al. The prognostic value of testicular microlithiasis as an incidental finding for the risk of testicular malignancy in children and the adult population: A systematic review. On behalf of the EAU pediatric urology guidelines panel. J Pediatr Urol 2021; 17:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson AC, Bauman JM, Light DE, et al. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. J Urol 2001; 166:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serter S, Gümüş B, Unlü M, et al. Prevalence of testicular microlithiasis in an asymptomatic population. Scand J Urol Nephrol 2006; 40:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton WD, Teefey SA, Santillan CS. Testicular microlithiasis: prospective analysis of prevalence and associated tumor. Radiology 2002; 224:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hentrich MU, Brack NG, Schmid P, et al. Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer 1996; 77:2109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyter DW, Bryant J, Thackeray R, et al. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995; 13:2540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003; 21:1922.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2997 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cancer statistics, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31059667" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31059667" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743088" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16395710" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12491506" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trends in the incidence of testicular germ cell tumors in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25030752" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25331158" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Recent trends in the incidence of testicular germ cell tumors in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140086" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Testicular cancer patterns in African-American men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110032" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increasing incidence of testicular germ cell tumors among black men in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29079210" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286463" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Differences in testis cancer survival by race and ethnicity: a population-based study, 1973-1999 (United States).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10597201" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Carcinoma in situ of the testis: review of biological and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6128821" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Carcinoma-in-situ of the undescended testis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6120755" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Testicular cancer in cryptorchids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3026550" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8955658" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8386582" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prevalence of bilateral testicular germ cell tumours and early detection based on contralateral testicular intra-epithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2173324" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Incidence of intratubular germ cell neoplasia in androgen insensitivity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9562456" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gonadal function in men with testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20026812" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16030303" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429248" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bilateral testicular germ cell tumours: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25542924" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33119475" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33356420" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1739626" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11081522" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Conundrum of the hereditary component of testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366298" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576844" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Familial testicular cancer and second primary cancers in testicular cancer patients by histological type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15172357" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Genetic predisposition to testicular germ-cell tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10820354" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Father-son testicular tumors: evidence for genetic anticipation? A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8611416" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Familial testicular cancer in Norway and southern Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16466541" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Familial risks in testicular cancer as aetiological clues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30967648" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26349679" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19162511" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12569597" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Syndromic aspects of testicular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749107" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Genetics and biology of adult human male germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10655070" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11571654" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8527395" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8308927" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical relevance of the i(12p) marker chromosome in germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35537936" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296647" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26503584" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Identification of four new susceptibility loci for testicular germ cell tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28604728" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27905446" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Genomic evolution and chemoresistance in germ-cell tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30676620" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7841064" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cancer incidence in men with Klinefelter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1425792" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Mediastinal germ cell tumour associated with Klinefelter syndrome. A report of case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2837589" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Genetic abnormalities in men with germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9112509" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Association of Down's syndrome and testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7640202" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Carney complex: the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10985153" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tumors of the testis in intersex syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10640893" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Management of males with 45,X/46,XY gonadal dysgenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8154078" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Gonadal tumors in disorders of sexual differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10897052" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421921" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : In utero exposure to female hormones and germ cell tumors in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18445826" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Persistent organochlorine pesticides and risk of testicular germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26560314" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774524" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association Between Marijuana Use and Risk of Cancer: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29093004" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501716" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20578177" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34598911" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Management of Testicular Microlithiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34217588" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The prognostic value of testicular microlithiasis as an incidental finding for the risk of testicular malignancy in children and the adult population: A systematic review. On behalf of the EAU pediatric urology guidelines panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11696707" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16809262" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prevalence of testicular microlithiasis in an asymptomatic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12147838" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Testicular microlithiasis: prospective analysis of prevalence and associated tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17617273" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640678" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Testicular germ cell tumors in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7595705" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743144" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Multicenter study of human immunodeficiency virus-related germ cell tumors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
